

[Cefotaxime](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.2. Watch group antibiotics](#)

Codes ATC: [J01DD01](#)

EMLc

Indication

Acute pyelonephritis Code ICD11: [GB51](#)

INN

Cefotaxime

Type de médicament

Chemical agent

Groupes d'antibiotiques

[WATCH](#)

Type de liste

Liste de base

Additional notes

3rd generation cephalosporin of choice for use in hospitalized neonates.

Formulations

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt)

Historique des statuts LME

Ajouté pour la première fois en 2017 ([TRS 1006](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Cefotaxime](#)

DrugBank

[Cefotaxime](#)

Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.

Recommandations de la LME : Acute pyelonephritis

Premier choix

Second choix

mild to moderate

Premier choix

[ciprofloxacin](#)

Second choix

[cefotaxime](#)

[ceftriaxone](#)

severe

Premier choix

[cefotaxime](#)

[ceftriaxone](#)

Second choix